Bottom line
FBIOX vs RYOIX: the short answer
FBIOX (Biotechnology Portfolio) and RYOIX (Biotechnology Fund) share a meaningful slice of their top holdings — about 53% by weight.
But FBIOX is far broader, holding 215 positions to 74 for RYOIX, so beyond the top names it adds exposure RYOIX doesn't have.
FBIOX is cheaper at 0.62% vs 1.38% — a difference of $76 a year per $10,000 invested.
Over five years, RYOIX returned +4.0% a year vs +3.5% for FBIOX (reporting dates differ).
Updated Nov 19, 2026
FBIOX vs RYOIX side by side
| FBIOX | RYOIX | |
|---|---|---|
| Type | Mutual fund | Mutual fund |
| Fund family | Fidelity | Guggenheim |
| Category | Technology Sector | Technology Sector |
| Expense ratio | 0.62% | 1.38% |
| Annual cost per $10k | $62 | $138 |
| 10-yr cost on $10k (prospectus) | $774 | $1,709 |
| Max front load | — | — |
| 12b-1 fee | 0% | 0% |
| 1-yr return | +36.4% | +30.7% |
| 5-yr return (annualized) | +3.5% | +4.0% |
| 10-yr return (annualized) | +6.9% | +5.9% |
| Best quarter | +33.6% | +28.3% |
| Worst quarter | −28.4% | −22.5% |
| Net assets (fund) | $5.3B | $136.8M |
| Number of holdings | 215 | 74 |
| Portfolio turnover | 45% | 75% |
| Returns as of | Apr 30, 2026 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | FBIOX | RYOIX | Difference |
|---|---|---|---|
| 2025 | +36.4% | +30.7% | +5.7% |
| 2024 | +7.3% | −0.7% | +8.0% |
| 2023 | +10.1% | +6.1% | +4.0% |
| 2022 | −15.9% | −13.1% | −2.8% |
| 2021 | −12.4% | +1.8% | −14.2% |
| 2020 | +38.3% | +22.1% | +16.3% |
| 2019 | +36.0% | +25.0% | +10.9% |
| 2018 | −10.7% | −9.0% | −1.8% |
| 2017 | +27.9% | +29.7% | −1.9% |
| 2016 | −23.7% | −19.5% | −4.2% |
Source: Fund prospectus bar charts
Holdings overlap
13 of FBIOX's top 25 holdings also appear in RYOIX's top 25.
| Holding | FBIOX | RYOIX |
|---|---|---|
| Abbvie Inc | 9.22% | 8.17% |
| Amgen Inc | 6.53% | 5.05% |
| Gilead Sciences Inc | 4.82% | 4.49% |
| Alnylam Pharmaceuticals Inc | 2.93% | 2.36% |
| Insmed Inc | 2.25% | 1.79% |
| Argenx Se | 2.25% | 1.48% |
| Revolution Medicines Inc | 2.02% | 2.48% |
| Jazz Pharmaceuticals Plc | 1.84% | 1.42% |
| Natera Inc | 1.41% | 2.12% |
| Moderna Inc | 1.28% | 2.15% |
| Biogen Inc | 1.26% | 2.13% |
| Roivant Sciences Ltd | 1.13% | 1.66% |
| Bridgebio Pharma Inc | 0.89% | 1.38% |
Source: SEC Form N-PORT
FBIOX top 10
- Krystal Biotech Inc — 10.58%
- Abbvie Inc — 9.22%
- Amgen Inc — 6.53%
- Gilead Sciences Inc — 4.82%
- Fidelity Revere Street Trust — 3.35%
- Alnylam Pharmaceuticals Inc — 2.93%
- Praxis Precision Medicines Inc. — 2.47%
- Insmed Inc — 2.25%
- Argenx Se — 2.25%
- Ascendis Pharma A/s — 2.04%
RYOIX top 10
- Abbvie Inc — 8.17%
- Amgen Inc — 5.05%
- Gilead Sciences Inc — 4.49%
- Vertex Pharmaceuticals Inc — 4.32%
- Regeneron Pharmaceuticals Inc — 2.93%
- Revolution Medicines Inc — 2.48%
- Alnylam Pharmaceuticals Inc — 2.36%
- Beone Medicines Ltd — 2.17%
- Moderna Inc — 2.15%
- Biogen Inc — 2.13%
FAQ
What is the difference between FBIOX and RYOIX?
Which is cheaper, FBIOX or RYOIX?
Should I own both FBIOX and RYOIX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.